On Friday, Juno Therapeutics Inc (NASDAQ:JUNO)’s shares inclined 3.42% to $52.05.
Celgene Corporation (CELG) and Juno Therapeutics, Inc. (JUNO) declared a global partnership for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.
Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, counting Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.
Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, counting Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.
Healthcare Trust Of America Inc (NYSE:HTA)’s shares gained 1.11% to $25.42.
Healthcare Trust of America, Inc. (HTA), declared that on Wednesday, July 29, before the market opens, it will report second quarter financial results. The Company will host a conference call and webcast on Wednesday, July 29, 2015 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) to review its financial performance and operating results for the quarter ended June 30, 2015.
Healthcare Trust of America, Inc. is a publicly owned equity real estate investment trust. The firm invests in the real estate markets of the United States. It is engaged in acquiring, owning and operating high-quality medical office buildings located primarily on-campus or associated with the nation’s leading healthcare systems. Healthcare Trust of America, Inc. was founded on April 20, 2006 and is based in Scottsdale, Arizona.
At the end of Friday’s trade, WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX)‘s shares surged 2.43% to $40.50.
WuXi PharmaTech (Cayman) Inc. (WX) declared that SynTheAll Pharmaceutical Co. Ltd. (STA), WuXi’s small-molecule manufacturing partner, has reached a contract in connection with a planned private placement of 7,160,000 common shares of STA stock, representing about 6% of STA’s current shares outstanding, for RMB 498,694,000 in cash, or about $80 million at current exchange rates. Purchasers in the private placement (comprised of 33 institutional investors in China) have agreed to a lock-up period of 12 months, the same as for STA and WuXi administration who purchased shares. None of the investors purchasing STA stock in the private placement are associated with WuXi. After giving effect to the private placement, WuXi will own 89.1% of STA’s shares outstanding. The closing of the private placement is subject to customary conditions and is predictable to close by the end of July 2015. In April 2015, STA accomplished the listing of its shares on the New Third Board, the over-the-counter stock exchange in China.
STA provides process chemistry services and manufactures small-molecule advanced intermediates and APIs for customer use in preclinical and clinical trials and for marketed small-molecule drugs. Its operations are located in the Waigaoqiao Free Trade Zone and Jinshan, both in Shanghai, and in Changzhou. STA does not comprise WuXi’s biologics manufacturing business. STA’s business is significantly more capital intensive than WuXi’s laboratory services business and is in the process of building new facilities in Changzhou to substantially enhance its production capacity. The proceeds of this new private placement will fund this capacity expansion and other investments necessary to support STA’s future growth.
Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services.
Community Health Systems (NYSE:CYH), ended its Friday’s trading session with 0.28% gain, and closed at $61.75.
Community Health Systems, Inc. (CYH) declared that it will provide an online Web simulcast and rebroadcast of its second quarter 2015 conference call.
The Company will issue a press release announcing its results on Monday, August 3, 2015, after the regular close of trading. The conference call is planned to start at 10:00 a.m. Central time, 11:00 a.m. Eastern time, on Tuesday, August 4, 2015. A live broadcast of the conference call will be accessible online at www.chs.net. To listen to the live call, please go to the web site at least 15 minutes early to register, download, and install any necessary audio software. The online replay will follow shortly after the call and continue through September 4, 2015.
Community Health Systems, Inc., together with its auxiliaries, provides general and specialized hospital healthcare services to patients in the United States. The company operates general acute care hospitals that offer a range of inpatient and outpatient medical and surgical services, such as general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, in addition to skilled nursing and home care services based on individual community needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
